Long term effects of therapeutically administered Ra-224 in ankylosing spondylitis patients
The health of ankylosing spondylitis patients was monitored in hospitals known to have treated significant numbers of patients with Ra-224. The majority of the patients were treated between 1948 and 1975 and most of them received one series of 10 weekly injections of about 1 MBq of Ra-224 each. This dosage leads to a cumulative alpha-dose of about 0.56 Gy to the marrow-free skeleton of a 70 kg man. Observed and expected cases for the exposure and control groups are compared, with emphasis on diseases which are known or implied to be associated with a former administration of Ra-224. The results reported are in line with those from animal experiments with bone seeking alpha-emitters given at very low dose rates, lower than those found to cause bone tumours.
Bibliographic Reference: Paper presented: Workshop on Thorotrast Induced Neoplastic Diseases, Heidelberg (DE), June 20-21, 1991
Availability: Text not available
Record Number: 199310621 / Last updated on: 1994-11-29
Original language: en
Available languages: en